The Manila Times13d
Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline
Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...
Euroapi: Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline
Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 ...
pharmaphorum4d
Ardelyx’s ambition to revolutionise kidney treatment
Raab co-founded Californian company Ardelyx in 2007 after working for years at Genzyme, the developer of phosphate binder Renagel (sevelamer hydrochloride). Ardelyx aim is to develop and ...
Frontiers8d
Crosstalk between ferroptosis and innate immune in diabetic kidney disease: mechanisms and therapeutic implications
Diabetic kidney disease (DKD) is a prevalent complication of diabetes mellitus (DM), and its incidence is increasing alongside the number of diabetes cases. Effective treatment and long-term ...
Frontiers21d
Thyroid hormone replacement therapy in dialysis/renal insufficiency patients
The kidney functions as both an excretory and a crucial endocrine organ, playing a significant role in the body’s metabolism, degradation, and excretion of thyroid hormones (TH) (1). TH play a ...
BMJ10d
Patient satisfaction with in-centre haemodialysis care: an international survey
Objectives To evaluate patient experiences of specific aspects of haemodialysis care across several countries. Design Cross-sectional survey using the Choices for Healthy Outcomes in Caring for ...